Welcome to our dedicated page for PRECIGEN SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah reported a tax-related stock sale. On May 28, 2026, he sold 42,703 shares of common stock at $4.36 per share in a sell-to-cover transaction to satisfy tax withholding obligations from restricted stock units that vested on May 23, 2026. Following this transaction, he continues to hold 497,751 shares of Precigen common stock directly, indicating he retains a substantial equity stake in the company.
PRECIGEN, INC. reported an insider stock transaction by Chief Legal Officer Donald P. Lehr. On May 28, 2026, he sold 29,131 shares of common stock at $4.36 per share. According to the footnote, this was a sell-to-cover transaction to satisfy tax withholding obligations from restricted stock units that vested on May 23, 2026. After the sale, he continues to hold 755,461 shares of Precigen common stock directly.
PRECIGEN, INC. President and CEO Helen Sabzevari reported a disposition of company stock tied to tax obligations. She sold 119,250 shares of Common Stock at $4.36 per share in a sell-to-cover transaction to satisfy tax withholding upon the vesting of restricted stock units on May 23, 2026. Following this transaction, she directly holds 3,768,872 shares of Precigen common stock.
Precigen, Inc. Chief Financial Officer Harry Thomasian Jr. exercised restricted stock units into common stock as part of his compensation. On May 23, 2026, he acquired 87,500 shares of common stock through the conversion of restricted stock units, with no open-market purchase or sale reported.
Following the transaction, he directly holds 596,419 shares of common stock and 87,500 restricted stock units. The footnotes explain that these RSUs were granted on June 26, 2025, with 50% vesting on May 23, 2026 and the remaining units vesting in equal quarterly installments over the next three years.
PRECIGEN, INC. Chief Commercial Officer Phil Tennant acquired 62,500 shares of common stock on May 23, 2026 through the exercise of restricted stock units. Following the transaction, he directly holds 169,641 common shares. The filing also shows 62,500 RSUs remaining, which will vest in equal quarterly installments over three years.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah exercised 90,000 restricted stock units into common stock as part of his equity compensation. Following the transaction, he directly holds 540,454 shares of common stock and 90,000 RSUs. The footnotes state that these RSUs were part of a June 26, 2025 grant, with 50% vesting on May 23, 2026 and the remainder scheduled to vest in equal quarterly installments over three years. No open-market purchases or sales were reported; this activity reflects routine vesting and conversion of equity awards.
PRECIGEN, INC. President and CEO Helen Sabzevari exercised restricted stock units that converted into 250,000 shares of common stock on May 23, 2026. Following the transaction, she directly holds 3,888,122 shares of common stock, reflecting an increase in her equity position.
The Form 4 also shows 250,000 restricted stock units outstanding after the transaction. Each RSU represents a contingent right to receive one share of Precigen common stock. The vested portion represents 50% of RSUs granted on June 26, 2025, with the remaining RSUs scheduled to vest in equal quarterly installments over the next three years.
PRECIGEN, INC. Chief Legal Officer Donald P. Lehr exercised restricted stock units into common stock as part of his compensation. He acquired 62,500 shares of common stock on May 23, 2026, increasing his direct holdings to 784,592 shares.
The 62,500 RSUs exercised correspond to 50% of an RSU grant made on June 26, 2025 that vested on May 23, 2026. The remaining portion of that grant, represented by 62,500 RSUs, is scheduled to vest in equal quarterly installments over the next three years.
Point72 Asset Management and affiliated filers report shared beneficial ownership of 6,741,861 shares of Precigen, Inc. Common Stock, representing 1.9% of the class as of March 31, 2026. The amount reported includes 97,500 shares issuable upon exercise of call options. The statement is filed on behalf of Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen; all three report no direct sole ownership and disclose shared voting and dispositive power over the 6,741,861 shares.
Precigen, Inc. reported sharply improved results for the quarter ended March 31, 2026, driven by the US launch of PAPZIMEOS for recurrent respiratory papillomatosis. Total revenues were $23.3 million, up from $1.3 million a year earlier, with $21.6 million from PAPZIMEOS sales.
The company’s net loss narrowed to $7.9 million, or $0.02 per share, compared with a net loss of $54.2 million, or $0.18 per share, in the prior-year quarter. Management highlighted approximately 400 patients enrolled in the PAPZIMEOS hub and reiterated that current cash, investments and expected PAPZIMEOS cash collections are anticipated to fund operations through cash flow break-even by the end of 2026.